CareDx (NASDAQ:CDNA) Shares Down 4.2%

CareDx, Inc (NASDAQ:CDNAGet Rating)’s stock price fell 4.2% during trading on Tuesday . The company traded as low as $19.60 and last traded at $19.62. 2,347 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 887,000 shares. The stock had previously closed at $20.49.

A number of research firms recently commented on CDNA. Raymond James dropped their price objective on CareDx from $90.00 to $52.00 and set a “strong-buy” rating on the stock in a report on Friday, February 25th. StockNews.com downgraded CareDx from a “hold” rating to a “sell” rating in a report on Friday, April 8th. Stephens began coverage on CareDx in a report on Monday, April 25th. They set an “overweight” rating and a $50.00 price target on the stock. BTIG Research lowered their price target on CareDx from $100.00 to $65.00 in a report on Monday, February 28th. Finally, Craig Hallum lowered their price target on CareDx from $106.00 to $87.00 in a report on Friday, February 25th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $72.80.

The company has a market capitalization of $1.08 billion, a P/E ratio of -21.31 and a beta of 0.83. The firm has a 50-day moving average price of $28.81 and a two-hundred day moving average price of $36.25.

CareDx (NASDAQ:CDNAGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07). CareDx had a negative net margin of 16.09% and a negative return on equity of 10.58%. The business had revenue of $79.42 million during the quarter, compared to the consensus estimate of $78.63 million. On average, equities analysts expect that CareDx, Inc will post -1.22 EPS for the current fiscal year.

In other CareDx news, Director Peter Maag sold 10,000 shares of CareDx stock in a transaction on Tuesday, April 5th. The shares were sold at an average price of $38.64, for a total transaction of $386,400.00. Following the sale, the director now owns 311,689 shares in the company, valued at $12,043,662.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Reginald Seeto sold 2,888 shares of CareDx stock in a transaction on Monday, March 21st. The stock was sold at an average price of $40.43, for a total transaction of $116,761.84. The disclosure for this sale can be found here. Insiders sold 18,567 shares of company stock valued at $640,336 over the last three months. 4.60% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Montag A & Associates Inc. boosted its stake in CareDx by 64.5% during the fourth quarter. Montag A & Associates Inc. now owns 579 shares of the company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. Pinebridge Investments L.P. acquired a new stake in shares of CareDx in the 4th quarter valued at $32,000. Lindbrook Capital LLC boosted its stake in shares of CareDx by 2,183.9% in the 4th quarter. Lindbrook Capital LLC now owns 708 shares of the company’s stock valued at $32,000 after purchasing an additional 677 shares in the last quarter. Sandy Cove Advisors LLC acquired a new stake in shares of CareDx in the 4th quarter valued at $45,000. Finally, Hardy Reed LLC acquired a new stake in shares of CareDx in the 1st quarter valued at $41,000.

About CareDx (NASDAQ:CDNA)

CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Featured Articles

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.